RxDoctor Payments Data

Satish Mallik, MD

Psychiatry · Moosic, PANPI 1568421451

Payments from drug & device makers

$19,883in general payments, 2019–2025

Across 1,384 payments — averaging $14.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Alkermes, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • plus $10K from 31 others

What the payments were for

  • Food & beverage$19,834100%
  • Education$490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,883 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$113,550
Medicare patients
398
Services billed
1,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl73$120,858
TrintellixVortioxetine Hydrobromide44$26,323
RexultiBrexpiprazole15$21,393
Lurasidone Hcl73$10,094
Ziprasidone Hcl38$7,145
Aripiprazole208$7,044
Duloxetine Hcl226$4,821
Desvenlafaxine Succinate ErDesvenlafaxine Succinate72$3,807
Quetiapine Fumarate200$3,600
Clomipramine Hcl15$3,596
Divalproex Sodium ErDivalproex Sodium55$3,335
Clonazepam362$2,879
Fluvoxamine Maleate33$2,667
Bupropion XlBupropion Hcl113$2,605
Trazodone Hcl231$2,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,525$120,85873 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$942$26,32344 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,286$21,39315 claims
Almatica Pharma LLCSertraline Hcl$285$853108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Moosic

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →